In a Phase I/II trial, convection-enhanced delivery of an engineered poliovirus yielded similar median overall survival compared to historical controls. However, a small subgroup of treated patients had extended survival past two years.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content